Safety of benznidazole use in the treatment of chronic Chagas' disease

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 5, 2012, Pages 1261-1266

  Hasslocher Moreno, Alejandro M ^a   do Brasil, Pedro E A A ^a   de Sousa, Andrea S ^a   Xavier, Sergio S ^a   Chambela, Mayara C ^a   Sperandio da Silva, Gilberto M ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

Author keywords

Adverse drug reactions; Naranjo algorithm; Treatment interruption; Trypanosoma cruzi

Indexed keywords

BENZNIDAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTONOMIC NEUROPATHY; CHAGAS DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; PERIPHERAL NEUROPATHY; SEX DIFFERENCE; SKIN DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL DISORDER;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTIPROTOZOAL AGENTS; CHAGAS DISEASE; CHRONIC DISEASE; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NITROIMIDAZOLES; YOUNG ADULT;

EID: 84859562550     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks027     Document Type: Article

References (26)

1. Jannin J, Salvatella R. Estimación Cuantitativa de la Enfermedad de Chagas en las Américas/Quantitative Estimation of Chagas Disease in the Americas. Montevideo: Organización Panamericana de la Salud [OPS/HDM/CD/425-06], 2006.
2. Moncayo Á, Silveira AC. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz 2009; 104: 17-30.
3. Schmunis GA, Yadon ZE. Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop 2010; 115: 14-21.
4. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 2001; 1: 92-100.
5. Croft SL, Barrett MP, Urbina JA. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol 2005; 21: 508-12.
6. Cançado JR. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 2002; 44: 29-37.
7. Marin-Neto JA, Rassi A Jr, Morillo CA et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 2008; 156: 37-43.
8. Pérez-Molina JA, Pérez-Ayala A, Moreno S et al. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009; 64: 1139-47.
9. de Andrade JP, Marin Neto JA, de Paola AA et al. I Latin American guidelines for the diagnosis and treatment of Chagas' heart disease: executive summary. Arq Bras Cardiol 2011; 96: 434-42.
10. Ministry of Health Brazil. Brazilian consensus on Chagas disease. Rev Soc Bras Med Trop 2005; 38: 11-4.
11. Viotti R, Vigliano C, Lococo B et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther 2009; 7: 157-63.
12. Altcheh J, Moscatelli G, Moroni S et al. Adverse events after the use of benznidazole in infants and children with Chagas disease. Pediatrics 2011; 127: e212-8.
13. Sosa-Estani S, Segura EL. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis 2006; 19: 583-7.
14. WHO Expert Committee. Control of Chagas disease. WHO Technical Report Series. Brasilia: WHO, 2002.
15. Bern C, Montgomery SP, Herwaldt BL et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 2007; 298: 2171-81.
16. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
17. WHO. The WHO Adverse Reaction Terminology-WHO-ART. Uppsala: WHO Collaborating Centre for International Drug Monitoring, 2005.
18. Coelho HL, Arrais PS, Gomes AP. Ceara State Pharmacovigilance System: a year of experience. Cad Saude Publica 1999; 15: 631-40.
19. Lauritsen JM, Bruus M. A Comprehensive Tool for Validated Entry and Documentation of Data. Odense: The EpiData Association, 2003.
20. SPSS Inc. SPSS Statistics 16.0. Chicago, IL: SPSS Inc., 2007.
21. Jannin J, Villa L. An overview of Chagas disease treatment. Mem Inst Oswaldo Cruz 2007; 102 Suppl 1: 95-7.
22. de Pontes VM, Souza Junior AS, Cruz FM et al. Adverse reactions in Chagas disease patients treated with benznidazole, in the State of Ceara. Rev Soc Bras Med Trop 2010; 43: 182-7.
23. Viotti R, Vigliano C, Armenti H et al. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 1994; 127: 151-62.
24. Sosa-Estani S, Armenti A, Araujo G et al. Treatment of Chagas disease with benznidazole and thioctic acid. Medicina (B Aires) 2004; 64: 1-6.
25. Viotti R, Vigliano C, Lococo B et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006; 144: 724-34.
26. Pinazo MJ, Munoz J, Posada E et al. Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob Agents Chemother 2010; 54: 4896-9.